AK-R215 Pharmacokinetic Study Phase I

AK-R215 Pharmacokinetic Study Pharmacokinetic Characteristics of AK-R215 in Comparison to Each Component Coadministered in Healthy Adult Male or Menopausal Female Valunteers.

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of AK-R215

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the safety and pharmacokinetics characteristics after administration of fixed dose combination or loose combination of AK-R215 in healthy adult male or menopausal female volunteers

Inclusion Criteria:

• BW is above 50kg and BMI is between 18.5 and 30.0
• Subject who agreed and signed on informed consent form prior to the study participation

Exclusion Criteria:

• Presence or history of clinically significant disease
• Treatment history of any drug which might affect IP within 10days
• History of other study drugs within 12weeks